- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04833764
Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis
October 14, 2021 updated by: Khanh Nguyen
The goal of this study is to determine the safety and tolerability or efficacy of adjunctive treatments (including rosuvastatin 20 mg daily) in combination with standard anticoagulation therapy (Factor Xa inhibitors) in patients with lower extremity deep vein thrombosis (DVT).
The efficacy of adjunctive treatments to prevent the development of post thrombotic syndrome (PTS) after DVT will be evaluated.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Post-thrombotic syndrome (PTS) is a significant complication that occurs up to 75% of patients after DVT.
Rosuvastatin is a HMGCoA reductase inhibitor that has anti-inflammatory effects.
In this study, the investigators will evaluate the safety and tolerability of combination standard anticoagulation therapy (e.g.
Factor Xa inhibitor, rivaroxaban, apixaban) and three months of 20 mg dose of rivaroxaban and its efficacy as prophylaxis against PTS after lower extremity DVT.
After the diagnosis of lower extremity DVT with either duplex venous ultrasound or other imaging, study participants will initiate standard rivaroxaban therapy as per standard medical care.
All consented participants in this trial will receive three months of rosuvastatin (20 mg daily dose).
Assessment of post thrombotic syndrome follow up will continue for 365 days from the time of DVT diagnosis or until resolution or stabilization of any clinically significant drug related adverse event, after which they will be considered off-study.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Khanh P Nguyen, MD
- Phone Number: 5034947145
- Email: nguykha@ohsu.edu
Study Contact Backup
- Name: Tahnee Groat, MPH
- Phone Number: 56888 503-220-8262
- Email: groat@ohsu.edu
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- VA Portland Health Care System (VAPORHCS)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women
- Diagnosis of a first episode of acute proximal leg DVT within 4 weeks of initial DVT diagnosis and without symptomatic pulmonary embolism (PE)
- Must have ECOG performance status ≤ 2
- Expected life expectancy of >2 years
- Before initiation of anticoagulation, must have adequate platelet count: Platelet count > 100 x 10^9/L,
- Before initiation of anticoagulation, must have adequate hemoglobin (Hgb) count: Hgb > 9 mg/DL
- Before initiation of anticoagulation, must have normal INR and PTT: INR ≤ 1.5 and aPTT≤40
Exclusion Criteria:
- Concurrent participation in another therapeutic clinical trial
- History of prior DVT in the previous 2 years
- Recurrent deep vein thrombosis (DVT)
- Established post thrombotic syndrome (PTS)
- Limb-threatening circulatory compromise
- Pulmonary embolism with hemodynamic compromise
- Deranged baseline coagulation profile before initiation of anticoagulation: INR > 1.5 or aPTT prolonged >40
- Active bleeding within last 3 months
- Anemia with Hemoglobin<9 mg/dL
- Thrombocytopenia with platelets < 100,000/ml
- Previously documented hypersensitivity to either the drug or excipients
- Any contraindication to anticoagulation or allergy to factor V inhibitors or ferumoxytol
- Any contraindication to magnetic resonance imaging (MRI) including metal implants or claustrophobia
- Severe hepatic impairment as defined by Childs-Pugh Class B or C
- Severe renal impairment with CrCl<30 ml/min,
- Taking any P-GP or strong CYP3A4 inhibitors or inducers
- History of major bleeding including history of gastrointestinal bleeding or intracranial bleeding
- Known history of bleeding diathesis
- History of chronic atrial fibrillation or stroke
- History of active cancer or malignancy within 1 year,
- Life expectancy <2 years.
- Patients requiring emergent or urgent surgery or procedures within the first 3 months of the study that cannot be postponed will be excluded.
- Patients who are breastfeeding or anticipate pregnancy
- Participant is pregnant or breastfeeding
- Participant is a prisoner (protected population)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rosuvastatin
Subjects will receive 20 mg daily dose of rosuvastatin for at least 3 months
|
Oral administration of 20 mg rosuvastatin for at least 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-thrombotic syndrome
Time Frame: 365 day
|
Incidence of post-thrombotic syndrome as measured by the Villalta Scale (score = or > 4).
Minimum score=0, Maximum score=33, and a higher score indicates worse outcome.
|
365 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of post-thrombotic syndrome (PTS)
Time Frame: 365 day
|
Villalta score severity of post-thrombotic syndrome
|
365 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Khanh P Nguyen, MD, Portland VA Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2021
Primary Completion (Anticipated)
June 1, 2025
Study Completion (Anticipated)
June 1, 2025
Study Registration Dates
First Submitted
April 2, 2021
First Submitted That Met QC Criteria
April 2, 2021
First Posted (Actual)
April 6, 2021
Study Record Updates
Last Update Posted (Actual)
October 15, 2021
Last Update Submitted That Met QC Criteria
October 14, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Peripheral Vascular Diseases
- Venous Insufficiency
- Phlebitis
- Thrombosis
- Venous Thrombosis
- Postthrombotic Syndrome
- Postphlebitic Syndrome
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Rosuvastatin Calcium
Other Study ID Numbers
- eIRB19051/M4069
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deep Vein Thrombosis Leg
-
Vetex Medical Ltd.CompletedDeep Vein Thrombosis LegIreland, Germany, Bulgaria, United Kingdom
-
Diakron PharmaceuticalsCompleted
-
Imperial College LondonWithdrawnDeep Vein Thrombosis | Deep Venous Thrombosis of LegUnited Kingdom
-
University of OklahomaPfizerCompleted
-
University Medical Center GroningenCompletedSuspected Upper Extremity Deep Vein ThrombosisAustria, Netherlands, Italy, Belgium, Switzerland, Germany, United States
-
National Taiwan University HospitalUnknownUpper Extremity Deep Vein Thrombosis, SecondaryTaiwan
-
University of Missouri-ColumbiaTerminatedDEEP VEIN THROMBOSISUnited States
-
MinaPharm PharmaceuticalsRecruitingProphylaxis of Deep Vein ThrombosisEgypt
-
UPECLIN HC FM Botucatu UnespCompletedProphylaxis of Deep Vein ThrombosisBrazil
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)CompletedSuspected Deep Vein ThrombosisCanada
Clinical Trials on Rosuvastatin
-
AstraZenecaCompletedDyslipidemia | Kidney DiseaseUnited States, Puerto Rico
-
Kobe UniversityCompletedCoronary Artery Disease Progression
-
Yuhan CorporationCompletedHypertension | HyperlipidemiaKorea, Republic of
-
Ottawa Hospital Research InstituteUnknownVenous ThromboembolismCanada, Norway
-
Gachon University Gil Medical CenterDaewoong Pharmaceutical Co. LTD.UnknownCoronary Artery DiseaseKorea, Republic of
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownHealthyKorea, Republic of
-
Alvogen KoreaCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Organon and CoCompleted